The class of drugs called the protein degraders, or better known as the "PROTACs: Proteolysis Targeting Chimeras", have gained significant momentum in the past decade with seminal work led by Crews et al. and other pioneering leaders to follow. Today, successful small molecule PROTAC interventional therapeutics have entered clinical trials for cancer treatment, with significant advancements occurring rapidly in the field to leverage this tool to investigate several undruggable targets for varied clinical indications. The objective of this symposium will be to introduce the emerging protein degrader tools (PROTACs and molecular glues) for drug discovery and highlight the successful application of these approaches to the innovation of novel therapeutics. The panel of world-leading speakers in this symposium will present on the evolution and emergence of the PROTACs, use cases of PROTACs across therapeutic areas of research. opportunities and challenges in the therapeutics application of this ground-breaking technology, and progress made, future expectations, and areas of growth in the field.